Stille

Stille EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Stille (STIL.ST) as of Oct 24, 2026 is 21.56. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 17.48 — a change of 23.33% (higher).

EV/EBITDA

21.56

YoY

23.33%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Stille is 2025 21.56 . EV/EBITDA (Enterprise Value to EBITDA) of Stille was 2024 17.48 . It decreases by 23.33% higher compared to the previous year.

The Stille EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
60.95 SEK
Jan 1, 2019
53.24 SEK
Jan 1, 2020
135.56 SEK
Jan 1, 2021
75.57 SEK
Jan 1, 2022
47.07 SEK
Jan 1, 2023
31.11 SEK
Jan 1, 2024
17.48 SEK
Jan 1, 2025
21.56 SEK
The Stille EV/EBITDA history
YEAREV/EBITDAYoY
21.56+23.33%
17.48-43.80%
31.11-33.91%
47.07-37.71%
75.57-44.26%
135.56+154.61%
53.24-12.65%
60.95-25.51%
81.82-13.98%
95.12-37.91%
153.20-88.91%
1,381.63—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stille Stock analysis

What does Stille do? Stille AB generates revenue by developing and selling medical equipment through two distinct business lines. The Surgery business area focuses on handcrafted, forged surgical instruments for open surgery, particularly in cardiovascular, reconstructive, and aesthetic plastic surgery. This segment produces essential tools such as scissors, forceps, artery forceps, needle holders, and clamps for medical professionals requiring precision instruments. The second revenue stream comes from the Patient Positioning area, which manufactures specialized procedure-specific tables. These devices are designed for cardiovascular surgery as well as gynecology, urology, and urodynamic examinations. By offering tailored positioning solutions for these specific medical fields, the company supports clinical procedures that require precise patient alignment. The company's operational structure includes wholly owned subsidiaries Stille Surgical Inc. and Stille Incentive AB, which support its manufacturing and distribution efforts. In 2013, the company adjusted its portfolio by selling its Sonesta business unit to ADDvise Lab Solutions publ AB, allowing it to focus on its core surgical and positioning equipment offerings. Stille is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stille stock

EV/EBITDA (Enterprise Value to EBITDA) of Stille is 21.56 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Stille changed from 17.48 to 21.56, representing a 23.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Stille since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Stille with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Stille

All Key Metrics — Stille